Business
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
FREMONT, Calif., March 16, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative
About this update from Ardelyx, Inc.
[{"type":"text","content":"FREMONT, Calif., March 16, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier, an industry veteran with deep biopharmaceutical commercial experience, has joined the Company's Board of Directors. Ms. Cadoret-Manier replaces Annalisa Jenkins, who stepped down from the board effective March 12, 2020 in order to be closer and more involved with her Board responsibilities in Europe. \n\n \n \n \n \n \n \n\n \n\"We are pleased to welcome Onaiza to our board of directors,\" said Mike Raab, president and chief executive officer of Ardelyx. \"Her wealth of experience, including commercialization and strategic planning for products at our stage, will be invaluable as we advance towards the potential launch and commercialization of tenapanor for the control of serum phosphorus in chronic kidney disease patients (CKD) on dialysis.\"\n\"With three successful Phase 3 trials for their lead therapeutic, tenapanor, this is an extremely exciting time for Ardelyx,\" said Ms. Cadoret-Mainer. \"I believe tenapanor has the potential to change the landscape for the control of serum phosphorus– finally, a fresh approach to phosphate control for patients. I'm looking forward to serving on the board and helping to guide the company through its transformation into a commercial organization with potential approval of its first marketed drug.\"\nMike Raab added, \"I want to thank Annalisa for her friendship, leadership and guidance over the past five years. She has been an extremely valuable member of the board of directors and it's been my pleasure to work with her.\" \nAnnalisa Jenkins joined the company's board of directors in 2015. Since joining the board, she has provided important contributions to help advance the company's clinical development programs with her broad range of industry experience. \nMs. Cadoret-Manier is an international commercialization and operations executive and life sciences industry veteran with over 30 years of experience driving growth for start-up and Fortune 500 companies. She has led and directed multiple new product launches with responsibility for product planning and commercialization through all phases of the product life ...